Ask AI
ProCE Banner Activity

Targeted Therapy in HR+/HER2- Breast Cancer: A Focus on Patient Communication to Promote Adherence to Therapy

Clinical Thought

In this commentary on HR-positive/HER2-negative breast cancer, experts discuss ways to mitigate and manage toxicities associated with oral targeted therapies with a focus on communication and shared decision-making.

Released: May 28, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, advanced-degree nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement evidence-based strategies to proactively identify, prevent, and manage adverse events associated with CDK4/6 inhibitors, oral SERDs, and PI3K/AKT-targeted therapies for patients with high-risk HR-positive/HER2-negative breast cancer in both adjuvant and metastatic settings

  • Individualize targeted therapy regimens based on patient- and disease-specific variables to optimize treatment outcomes for patients with high-risk HR-positive/HER2-negative breast cancer

  • Apply enhanced patient communication and shared decision-making skills in educating, monitoring, and supporting patients receiving targeted therapies to improve adherence and clinical outcomes

Disclosure

Primary Author

Kayla Freeman, DNP, APRN, FNP-C, has no relevant financial relationships to disclose.

Kimberly Podsada, MSN, NP-C, CNS: consultant/advisor/speaker: AstraZeneca/Daiichi Sankyo, Gilead, Lilly, Pfizer.

Cierra K. Ryan, PA-C, has no relevant financial relationships to disclose.